Epi-Caine, Epinephrine 0.025% Lidocaine HCL 0.75% Solution for Intraocular Injection, 1 ml, Singl...
FDA Drug Recall #D-0130-2023 — Class II — December 22, 2022
Recall Summary
| Recall Number | D-0130-2023 |
| Classification | Class II — Moderate risk |
| Date Initiated | December 22, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Pine Pharmaceuticals, LLC |
| Location | Tonawanda, NY |
| Product Type | Drugs |
| Quantity | 11,453 vials |
Product Description
Epi-Caine, Epinephrine 0.025% Lidocaine HCL 0.75% Solution for Intraocular Injection, 1 ml, Single Dose Vial, Compounded by Pine Pharmaceuticals, 355 Riverwalk Pkwy, Tonawanda, NY 14150. NDC 69194-0948-1
Reason for Recall
CGMP Deviations: Raw material recalled by repackager, due to discoloration.
Distribution Pattern
Nationwide to medical facilities.
Lot / Code Information
Lot # 62881, Exp 12/25/2022; 62923, Exp 12/26/2022; 63066, Exp 01/03/2023; 63067, Exp 01/01/2023; 63103, Exp 01/02/2023; 63120, Exp 01/03/2023; 63219, 63226, Exp 01/08/2023; 63263, Exp 01/09/2023; 63380, 63381, Exp 01/15/2023; 63433, Exp 01/16/2023; 63455, Exp 01/17/2023; 63537, Exp 01/22/2023; 63580, Exp 01/23/2023; 63721, Exp 01/29/2023; 63792, Exp 01/31/2023; 63888, Exp 02/05/2023; 63930, Exp 02/06/2023; 63959, Exp 02/07/2023; 64079, Exp 02/13/2023; 64109, Exp 02/14/2023; 64239, Exp 02/21/2023.
Other Recalls from Pine Pharmaceuticals, LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0059-2024 | Class II | Lidocaine-phenylephrine 1%-1.5% 1mL Single Dose... | Oct 2, 2023 |
| D-0057-2024 | Class II | Cefuroxime 4mg /0.4 mL (10 mg/mL), 1mL syringe,... | Oct 2, 2023 |
| D-0058-2024 | Class II | Moxifloxacin in Balanced Salt Solution 400 mcg/... | Oct 2, 2023 |
| D-0055-2024 | Class II | Tropi-Phen (Tropicamide 1% phenylephrine HCl 2.... | Oct 2, 2023 |
| D-0061-2024 | Class II | Calcium chloride Solution for Intravenous Injec... | Oct 2, 2023 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.